Physician profile
Gregory D Layton
NPI 1104881986
$2,316.29
in general payments reported to CMS, 2019-2025
31 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $92.74 · 2021: $221 · 2022: $381 · 2023: $616 · 2024: $332 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $428.83 | 2019-2025 | |
| Hologic Sales and Service, LLC | $234.49 | 2019-2025 | Novasure, Omni Hysteroscope, Myosure Tissue Removal Device |
| Organon LLC | $165.24 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $148.79 | 2022-2024 | |
| Stryker Corporation | $148.46 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.48 | 2019-2023 | |
| Samsung Hme America, INC. | $103.17 | 2025 | |
| Daiichi Sankyo INC. | $91.90 | 2019-2021 | |
| Gynesonics, INC. | $91.53 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biogen, INC. | $78.67 | 2024-2025 | Zurzuvae |
| Myriad Women'S Health, INC. | $71.16 | 2023 | Myrisk |
| Coopersurgical, INC. | $66.84 | 2022-2024 | Paragard T 380a |
| Myovant Sciences INC. | $63.75 | 2022 | |
| Shield Therapeutics INC | $60.74 | 2023-2024 | Accrufer |
| Therapeuticsmd, INC. | $53.82 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $51.16 | 2023 | Myfembree |
| Millicent US INC | $36.32 | 2019-2020 | |
| Optumhealth Care Solutions, LLC | $33.16 | 2024-2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Cook Medical LLC | $29.82 | 2023 | Guardia, Cook |
| Smith+Nephew, INC. | $29.39 | 2024-2025 | Pico 7, Pico 14 |
| Dexcom, INC. | $24.76 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $19.21 | 2025 | |
| Baxter Healthcare | $19.17 | 2024 | Perclot |
| Pacira Pharmaceuticals Incorporated | $18.38 | 2022 | |
| Minerva Surgical, INC | $18.00 | 2019 | |
| Agile Therapeutics, INC. | $18.00 | 2023 | Twirla |
| Merck Sharp & Dohme LLC | $16.41 | 2019 | |
| Boston Scientific Corporation | $16.24 | 2019 | |
| Evofem Biosciences, INC. | $16.16 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.53 | 2019 | |
| Meditrina | $10.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Layton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.